RxDoctor Payments Data

David Jones, MD

Critical Care Medicine · Tyler, TXNPI 1366440596

Payments from drug & device makers

$8,623in general payments, 2019–2025

Across 439 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Mylan Specialty L.p.$529
  • Jazz Pharmaceuticals Inc.$495
  • Boehringer Ingelheim$468
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$1,39016%
  • Food & beverage$6,98081%
  • Education$1702%
  • Gifts$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,623 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$163,703
Medicare patients
740
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate18$188,554
Trelegy ElliptaFluticasone/Umeclidin/Vilanter193$156,396
Fasenra PenBenralizumab11$61,146
Breztri AerosphereBudesonide/Glycopyr/Formoterol37$24,450
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$21,101
Breo ElliptaFluticasone/Vilanterol36$19,879
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,711
Arnuity ElliptaFluticasone Furoate25$5,118
Albuterol Sulfate HfaAlbuterol Sulfate122$4,907
Varenicline Tartrate11$3,945
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,811
SymbicortBudesonide/Formoterol Fumarate17$3,793
Ventolin HfaAlbuterol Sulfate45$3,148
Wixela InhubFluticasone Propion/Salmeterol16$2,977
BreynaBudesonide/Formoterol Fumarate13$1,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$468$209,65540 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,322$198,105284 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,148$28,24454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →